| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02071927 | Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL) | Drug: CB-839|Drug: CB-Aza | Calithera Biosciences, Inc | Phase 1 | 2014-03-01 | 2017-02-07 |
| NCT03047993 | Myelodysplastic Syndrome|Other Diseases of Blood and Blood-forming Organs | Drug: CB-839|Drug: Azacitidine | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Calithera Biosciences, Inc | Phase 1|Phase 2 | 2017-04-01 | 2017-02-06 |
| NCT02944435 | Healthy Volunteers | Drug: CB-839 Capsules|Drug: CB-839 Tablets | Calithera Biosciences, Inc | Phase 1 | 2016-10-01 | 2017-01-03 |
| NCT02071888 | Non-Hodgkin's Lymphoma (NHL)|Multiple Myeloma|Waldenstrom's Macroglobulinemia (WM)|Diffuse Large B-cell Lymphoma (DLBCL),|Other B-cell NHL Subtypes, Including WM|T-cell NHL | Drug: CB-839|Drug: CB-839 and low dose dexamethasone|Drug: CB-839, pomalidomide, and low dose dexamethasone | Calithera Biosciences, Inc | Phase 1 | 2014-02-01 | 2016-04-29 |
| NCT02861300 | Colorectal Cancer|Colon Cancer|Rectal Cancer|Solid Tumor | Drug: CB-839|Drug: Capecitabine | Case Comprehensive Cancer Center | Phase 1|Phase 2 | 2016-08-01 | 2016-09-28 |
| NCT02771626 | Clear Cell Renal Cell Carcinoma|Melanoma|Non-small Cell Lung Cancer | Drug: CB-839|Drug: Nivolumab | Calithera Biosciences, Inc | Phase 1|Phase 2 | 2016-08-01 | 2017-01-19 |
| NCT02071862 | Solid Tumors|Triple-Negative Breast Cancer|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Mesothelioma|Fumarate Hydratase (FH)-Deficient Tumors|Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)|Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors|Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations|Tumors Harboring Amplifications in the cMyc Gene | Drug: CB-839|Drug: Pac-CB|Drug: CBE|Drug: CB-Erl|Drug: CBD|Drug: CB-Cabo | Calithera Biosciences, Inc | Phase 1 | 2014-02-01 | 2016-08-18 |
| NCT03057600 | Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer | Drug: Pac-CB | Calithera Biosciences, Inc | Phase 2 | 2017-05-01 | 2017-02-17 |
